Healthcare Biz Review: J&J’s NEW TB Drug, Arena GIVES BACK Again
Amarin (NASDAQ:AMRN) nears receiving a long-sought patent for its top drug candidate, AMR101, after the USPTO issues a Notice of Allowance supporting the use of the fish-oil heart med in patients with high triglycerides. Such a notice is typically issued following a decision by regulators that a patent can be granted from an application. An FDA ruling on AMR101 is expected in July.
Johnson & Johnson (NYSE:JNJ) is requesting an accelerated FDA approval for bedaquiline, which is the first new type of medication for the treatment of tuberculosis in more than four decades, and is the first for specifically fighting the increasingly common strain of TB that is resistant to multiple drugs. The filing is supported by data from the firm’s Phase II trial.
Arena Pharmaceuticals (NASDAQ:ARNA) gave back more (but not all) of the gigantic gains it saw following FDA approval of its weight-loss drug Belviq. However, Vivus (NASDAQ:VVUS) shares are still advancing ahead of an FDA decision on the firm’s Qnexa diet drug scheduled for July 17.
Don’t Miss: Here are the STUDS and DUDS of the DOW for 2012.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.